Here’s whether IGC Pharma, Inc. (IGC) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Bearish.
🔴
Bearish
Positives: 50-day MA is rising (+0.39% over 10 days). Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); RSI 22 — oversold; weak 1-year return of -15.0%. Currently 42.2% off its 52-week high. Score: -4/7.
IGC is trading below its 200-day MA ($0.33) — a key warning sign the longer-term trend is under pressure. An RSI of 22.0 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of -15.0% compares to +27.9% for SPY (trailed the market by 42.9%). The current 42.2% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.
$10,000 invested 1 year ago→ $8,498 today
vs. S&P 500 (SPY) — same period trailed market by 42.9%